Vyepti: Now Available in Australia!



After yesterday's exciting news of Vyepti being on the July 2022 PBAC Agenda, we can now announce that Vyepti® (eptinezumab) is now available to prescribe in Australia for the preventive treatment of migraine in adults. It is administered as a 30-minute IV infusion every 12 weeks.

Vyepti is available via the private market and is not yet listed on the PBS. Because of this the price is high - as seen with other private scripts.

The price of the medication will start at $1,800 per quarter. This is equal to one infusion. The total price of the medication and IV infusion for patients will vary depending on the place of purchase and site of administration.

To assist in access to treatment, Lundbeck has developed a Coordinated Access Network (C.A.N.). The C.A.N. is a collaboration between Lundbeck and participating private hospitals and clinics to facilitate the IV infusion of Vyepti.

Details of the C.A.N., including out of pocket expenses, can be discussed with your Neurologist.

Patients have a number of infusion service options available including, at their neurologist’s clinic or with a participating C.A.N. provider.

For new patients, via the Coordinated Access Network, the first 12 weeks of treatment (that is, one infusion with one dose of 100mg only), will be provided by Lundbeck free of charge (limited to 300 patients).

For more information on CGRP Medications CLICK HERE 

Showing 1 reaction

  • Sarah Moseley
    published this page in News 2022-03-31 18:24:27 +1000